Skip to content

A Comparative Study on the Clinical Efficacy of Eolengfang Traditional Decoction and Formulated Granules in the Treatment of Qi Stagnation and Blood Stasis Type Endometriosis

A Comparative Study on the Clinical Efficacy of Eolengfang Traditional Decoction and Formulated Granules in the Treatment of Qi Stagnation and Blood Stasis Type Endometriosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001436
Enrollment
Unknown
Registered
2026-06-08
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Traditional Decoction Group:TCM Decoction Group: Eleng Formula (Sanleng 10g, Ezhu 10g, Danshen 15g, Yujin 10g, Chishao 15g, Biejia 10g, Zhiqiao 15g). Prepared by hospital pharmacy. One dose/day, twice
Formula Granule Group:Traditional Chinese Medicine (TCM) Granule Group: Receive the Chinese herbal formula "Eleng Formula" in the form of concentrated granules, consisting of: Sparganii Rhizoma (Sanle

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1)Diagnosed clinically or surgically with endometriosis, accompanied by dysmenorrhea, pelvic pain, or dyspareunia, with a VAS score =3; 2) Diagnosed in traditional Chinese medicine as "qi stagnation and blood stasis syndrome" related to endometriosis-associated pain; 3) Age =18 years, not postmenopausal, with a regular menstrual cycle (21~35 days); 4) Negative urine pregnancy test before enrollment, and contraception during treatment; 5),; 6) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1)Use of sex hormone medications within the past 3 months prior to enrollment; 2) Women with other gynecological diseases, such as post pelvic inflammatory disease sequelae or gynecological malignancies; 3) Lactating women; 4) Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic system diseases, or malignant tumors; patients with mental disorders; or those with a history of severe drug allergy or allergy to known drug components; 5) Patients scheduled for surgical treatment or other treatment regimens in the near future; 6) Patients currently participating in or who have participated in other clinical trials within the past 3 months prior to this study.

Design outcomes

Primary

MeasureTime frame
VAS;

Secondary

MeasureTime frame
EHP-5;serum CA125 level;Endometriosis lesion volume;

Countries

China

Contacts

Public ContactLiang Xuefang

Guangdong Provincial Hospital of Traditional Chinese Medicine

liangxuefang2006@126.com13926082916

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026